Karyopharm Therapeutics Inc - KPTI STOCK NEWS

Karyopharm Therapeutics (NASDAQ: KPTI) announced the start of patient dosing in two new Phase 2 and 1/2 clinical studies for XPOVIO® (selinexor) in advanced melanoma and treatment-naïve myelofibrosis. The Phase 2 study will assess XPOVIO combined with Keytruda® in patients resistant to prior treatments. The Phase 1/2 study will evaluate XPOVIO with Jakafi® in treatment-naïve myelofibrosis patients. These studies follow promising preclinical and earlier clinical data, highlighting the ongoing need for innovative cancer therapies.

Karyopharm Therapeutics (Nasdaq: KPTI) announced that it granted stock options to newly hired employees, including 125,000 shares to Ms. Sohanya Cheng, Senior VP, Sales and Commercial Operations, as an inducement for joining the company. The options have an exercise price of $10.32 per share, matching the closing price on June 30, 2021. Options vest over four years and may vest earlier upon termination without cause or a change in control event. This move aligns with Nasdaq Listing Rule 5635(c)(4) on compensatory stock option grants.

Karyopharm Therapeutics (NASDAQ: KPTI) announced an expanded royalty agreement with HealthCare Royalty Management for up to $100 million in financing to support the development of XPOVIO® (selinexor) and other programs. The initial $60 million has been received, with potential for two additional $20 million payments tied to milestones. XPOVIO is approved for multiple hematologic malignancies in the U.S. and has conditional marketing in Europe for multiple myeloma. Karyopharm expects the financing to sustain operations into mid-2023.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the selection of nine abstracts for virtual presentation at the European Hematology Association (EHA) 2021 Virtual Congress from June 9-17, 2021. The abstracts showcase clinical data on XPOVIO® (selinexor), including subgroup analyses from the Phase 3 BOSTON study and updated data from the Phase 1b/2 STOMP study. Notably, an oral presentation will focus on the combination treatment achieving a 78% overall response rate among multiple myeloma patients. This highlights Karyopharm's ongoing commitment to advancing cancer therapies.

Karyopharm Therapeutics (KPTI) reported positive Phase I/II results for eltanexor, a treatment for hypomethylating agent refractory myelodysplastic syndrome (MDS), during the ASCO Annual Meeting. Out of 15 evaluable patients, 47% achieved marrow complete response (mCR), and the total disease control rate was 80%. Notably, patients with mCR had a median overall survival (mOS) of 11.86 months, compared to 8.67 months for those without mCR. Eltanexor may offer a more tolerable option compared to first-generation inhibitors, with trials ongoing in Asia Pacific markets.

Karyopharm Therapeutics (Nasdaq: KPTI) announced significant management changes aimed at enhancing its commercial operations, including the appointment of Sohanya Cheng as Senior Vice President of Sales and Commercial Operations. Payman Darouian will oversee marketing for the company's lead product, XPOVIO (selinexor), while former executives John Demaree and Perry Monaco will leave to pursue other opportunities. Cheng, with 17 years in biopharmaceuticals, previously led marketing at Arrowhead Pharmaceuticals and has extensive oncology experience, contributing to the company's strategy for multiple myeloma and lymphoma.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the commercial availability of three new strength tablets for XPOVIO, following FDA approval on April 15, 2021. The new strengths of 40 mg, 50 mg, and 60 mg supplement the existing 20 mg tablet, enhancing patient compliance and treatment flexibility. XPOVIO is a first-in-class oral Selective Inhibitor of Nuclear Export (SINE) approved for multiple myeloma and diffuse large B-cell lymphoma. The new strengths do not alter the drug's efficacy or safety profile.

Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 2, 2021, that the UK's Medicines & Healthcare Products Regulatory Agency granted conditional marketing authorization for NEXPOVIO® (selinexor) in combination with dexamethasone to treat multiple myeloma in adult patients who have undergone at least four prior therapies. This authorization is based on positive results from the Phase 2b STORM study, which reported a 26% overall response rate in heavily pretreated patients. Continued authorization will depend on confirming clinical benefits in further trials.

Karyopharm Therapeutics (Nasdaq: KPTI) announced on June 1, 2021, the grant of stock options totaling 24,600 shares to six newly-hired employees as an inducement related to their employment. The options were granted at an exercise price of $9.28 per share, equal to KPTI's closing stock price on May 28, 2021. Each option will vest over four years, with the first 25% vesting on the one-year anniversary of employment. If a 'change in control event' occurs, options may become immediately exercisable upon certain termination conditions.